SUBSCRIBE
SUBSCRIBE

Cullinan Therapeutics

NEWS
Business
Top 20 Life Science Startups to Watch in 2019
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
November 6, 2018
 · 
12 min read
 · 
Mark Terry
Investor
Biotech Bay
Shhhh.....There’s a New T-Cell Strategy
Rumor is there’s a new approach to fighting cancer in town.
October 23, 2017
 · 
1 min read
 · 
Karl Thiel
Cullinan Oncology Emerges With $150 Million and a Roster of All-Star Biotech Scientists
Business
Cullinan Oncology Emerges With $150M and a Roster of All-Star Biotech Scientists
October 3, 2017
 · 
2 min read
Load More
AWARDS
  • NextGen Class of 2019
JOBS
IN THE PRESS
Press Releases
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
November 14, 2024
 · 
9 min read
Press Releases
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 7, 2024
 · 
10 min read
Press Releases
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
November 5, 2024
 · 
1 min read
Press Releases
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
November 5, 2024
 · 
7 min read
Press Releases
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
October 16, 2024
 · 
7 min read
Press Releases
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
September 17, 2024
 · 
7 min read
Press Releases
Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus
September 16, 2024
 · 
6 min read
Press Releases
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
September 16, 2024
 · 
8 min read
Press Releases
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
August 28, 2024
 · 
2 min read
Business
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 8, 2024
 · 
13 min read
Load More